P01-02DETECTION OF CERVICAL HUMAN PAPILLOMAVIRUS IN WOMEN ATTENDING CERVICAL CANCER SCREENING BY VISUAL INSPECTION IN COTE D’IVOIRE

01. Viral and molecular biology
A. Ouattara 1, A. Yéo 2, E. Kouamé-Blavo 2, K.P. Oura 3, T.F. Koffi 4, H. Faye-Kétté 5, M. Dosso-Brettin 5.
1University Felix Houphouet Boigny of Cocody-Abidjan (Côte d'Ivoire), 2Institut Pasteur Cote d'Ivoire-Abidjan (Côte d'Ivoire), 3Service de Gynécologie. Hopital Général Abobo Sud-Abidjan (Côte d'Ivoire), 4University Felix Houphouet Boigny-Abidjan (Côte d'Ivoire), 5University Felix Houphouet Boigny-Abidjan, Institut Pasteur (Côte d'Ivoire)

Background / Objectives

 Human papillomaviruses (HPV) cause precancerous lesions and cancers of the cervix. In Côte d'Ivoire, cervical cancer screening program based on visual inspection is the gold standard. This study aims to detect High risk (HR) HPV DNA on women attending for cervical cancer screening program based on visual inspection after application of acid acetic then lugol


Methods

From March to December 2015, endocervical samples from women attending cervical screening were tested for some HR-HPV. HPV DNA was amplified using PGMY09 /11 primers which generated 450 base pairs at the L1 region. The samples harboring HPV DNA were genotyped using the multiplex PCR with HPV 16, 18, 31, 33, 35, 45 and 51 primers.


Results

The mean age of this population was 32 years. On 339 women enrolled on visual inspection 6.19% were positive. HPV DNA was obtained in 9.73 of the population. Thirty-one of 33 samples (93.93.%) of HPV DNA+ were genotyped using multiplex PCR testing for HPV 16,18, 31, 33, 35, 45 and 51 Of those women with HPV DAN+.  28.57% had a single infection while 71.43% had a multiple infection. HPV genotypes prevalence were the followed: HPV 16 (30.00%), HPV 18 (25.00%), HPV35 (20.00%), HPV 45 (20.00%), HPV 51 (3.30%) and HPV 33 (1.60%). By using PCR as gold standard VIA sensitivity was 16.12% and specificity 95.45 %


Conclusion

HPV prophylactic vaccine would prevent 33.33% of HR HPV infection with the 2v, 33.33% with the 4v and 66.66 % with the 9v vaccines respectively. In Cote d'Ivoire screening for cervical cancer with HR HPV testing and triaging for treatment with visual inspection would represent a very efficient prevention of cervical cancer program. 


References

Castellsague X., de Sanjose S., Aguado T., Louie K.S., Bruni L., Munoz J., Diaz M., Irwin K., Gacic M., Beuavais O., Albero G., Ferrer E., Byrne S., Bosch F.X.(2007). HPV and cervical cancer in the world, Report. WHO/ICO Information Centre on HPV and cervical cancer (HPV Information Centre).

Ausubel FM, Brent R, Kingston R E., Moore D D. (1999).Short Protocols in Molecular Biology. New York: Greene Pub. Associates and WileyInterscience

Bosch  XavierF.  , BurchellAnn N. ,Schiffman Mark ,  GiulianoAnna R. ,  de SanjoseSilvia,LaiaBruni, Tortolero-Luna Guillermo , KjaerSusanne Kruger , Muñoz Nubia . (2008). Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia. Vaccine. 26 (sup 2) K1 – K16.